|
Short CV
|
Since 1999 - professor of biomedical engineering, since 1994 - deputy director of the Institute of Biocybernetic and Biomedical Engineering Polish Academy of Science, since 1989 - head of laboratory of Biomedical Engineering Methods for Support of Intensive Therapies in the Institute of Biocybernetics and Biomedical Engineering Polish Academy of Sciences.
2003 -2004 member of the Interim Executive Board and since 2005 member of the Council of the European Alliance for Medical and Biological Engineering and Science, 2001- 2003 member of the Protem Group, since 1998 - Governor in the European Society for Artificial Organs, since 1998 he is appointed as a “Visiting Professor” in the Donau University, Krems, Austria.
He spent as a visiting scientist over 2 years in USA (Cleveland Clinic Foundation) , 6 months in France (University of Compiegne) and few months in Germany (Institute for Diabetes, Ulm) and Japan (Nara Institute of Science and Technology).
He has published as an author and coauthor 188 publications including chapters, papers and conferences materials. He is an author and coauthor of 15 polish and international patents and 36 expert reports granted by Austrian, German, Japanese, French, Scottish and Polish scientific institutions.
He is a Section Editor in the International Journal of Artificial Organs (section - Artificial Pancreas, Diabetes and Endocrinology), member of the editorial board of the Journal of the Biocybernetics and Biomedical Engineering Polish Academy of Sciences and reviewer in many of the international journals from the fields of diabetes treatment and artificial organs.
His current research interests concern: artificial internal organs for metabolic support (in particular artificial pancreas/diabetes treatment, artificial kidney), blood purification processes by membranes techniques, drug delivery systems, technical support for intensive treatments.
|
|
Abstract
|
Diabetes is recognized as one of the most severe health problem in the world. It is the leading cause of kidney failure, blindness in adults, nervous system damage and amputations, as well as the major risk factor for heart disease, stroke and birth defects. It is currently one of the most costly diseases in both human and economic terms.
Diabetes is a group of metabolic diseases characterized by elevated level of the glucose concentration (hyperglycaemia) resulting from defects in insulin secretion by pancreas, insulin action or both.
There are several methods, which should in efficient way substitute the lost function of the pancreatic ß-cells like: biological approach, i.e. pancreas and islets transplantation and bio-technical solutions, so called hybrid artificial pancreas, which are related to application of the micro and macro-encapsulation of the pancreatic islets. However, despite many years of efforts none of these methods is routinely used for treatment of diabetes.
Currently for ambulatory insulin-treated diabetics only application of the intensive therapy can effectively delay development and progression of , the most critical for patients, life-threatening late complications of diabetes. An ideal intensive insulin treatment should mimic secretion of insulin by ß-cells in healthy persons as close as possible. Technical realization of such a treatment should consists of: an effective monitoring of the patient glycemic control and accurate delivery of insulin according to the established algorithm.
During last years technical support of the diabetes treatment is focused mainly on: (a) the most crucial issues of the blood glucose measurements, that is noninvasiveness and continuous monitoring, (b) application of the telematic systems leading to better education and more frequent contacts between patient and physician and (c) development of the new, less invasive, forms of insulin delivery. Another important technical solutions of the diabetes treatment pertains to design and development of the electromechanical artificial pancreas realized as a portable and fully implantable close loop system.
The main objective of presentation is to discuss the most interesting and important recent technical developments of the intensive insulin treatment, including own projects, stressing the existing problems and reviewing the best applied solutions.
|
